{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:40:48Z","timestamp":1792172448136,"version":"4.4.0"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":128,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA280827"],"award-info":[{"award-number":["R01 CA280827"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5 P01CA148600-03"],"award-info":[{"award-number":["5 P01CA148600-03"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR-12206-17"],"award-info":[{"award-number":["SCOR-12206-17"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA211044"],"award-info":[{"award-number":["R01 CA211044"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>CD70 is highly expressed in many cancers, including multiple myeloma. We show in two cohorts of patients with multiple myeloma that CD70 is elevated in several high-risk disease categories and correlates with poor survival. These findings were validated using single-cell RNA sequencing, flow cytometry, and IHC. Moreover, we demonstrate the feasibility of targeting CD70 in myeloma using NK cells engineered with a chimeric antigen receptor (CAR) incorporating the CD70 cognate receptor CD27 and IL-15 (CAR27\/IL-15). CAR27\/IL-15 NK cells exerted potent in vitro and in vivo cytotoxicity against CD70+ multiple myeloma cells, comparable with CAR27\/IL-15 T cells, and remained effective in BCMA knockout models. Collectively, these results establish CD70 as a promising therapeutic target for high-risk multiple myeloma, particularly for patients who relapse after BCMA-directed therapy, providing preclinical support for the ongoing phase I\/II clinical trial of CD70-targeting CAR NK cells (NCT05092451).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We demonstrate that CD70 expression is elevated in patients with high-risk multiple myeloma and in patients with t(4;14) translocation. CD70-targeting CAR NK cells exhibit potent cytotoxicity against CD70+ multiple myeloma cells and significantly improve survival in xenograft mouse models of multiple myeloma, even in the absence of BCMA expression.<\/jats:p>\n                    <jats:p>See related commentary by Benson Jr and Caligiuri, p. 166<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0130","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:46:00Z","timestamp":1761594360000},"page":"234-249","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-267X","authenticated-orcid":false,"given":"Paul","family":"Lin","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-9321","authenticated-orcid":false,"given":"Sunil","family":"Acharya","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5396-7691","authenticated-orcid":false,"given":"Francia","family":"Reyes-Silva","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-0454","authenticated-orcid":false,"given":"Rafet","family":"Basar","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-6208","authenticated-orcid":false,"given":"Nadima","family":"Uprety","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-7934","authenticated-orcid":false,"given":"Luz Yurany","family":"Moreno Rueda","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-945X","authenticated-orcid":false,"given":"Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"4Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8626-1919","authenticated-orcid":false,"given":"April L.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6711-3034","authenticated-orcid":false,"given":"Pinaki P.","family":"Banerjee","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9328-1250","authenticated-orcid":false,"given":"Dexing","family":"Fang","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-1751","authenticated-orcid":false,"given":"Chenyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-9274","authenticated-orcid":false,"given":"Ana Karen","family":"Nunez Cortes","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2193","authenticated-orcid":false,"given":"Luciana","family":"Melo Garcia","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"5Department of Medicine, Universit\u00e9 Laval, Quebec City, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-8397","authenticated-orcid":false,"given":"May","family":"Daher","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7096-0064","authenticated-orcid":false,"given":"Luis","family":"Muniz-Feliciano","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2638-0825","authenticated-orcid":false,"given":"Gary M.","family":"Deyter","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0661-3636","authenticated-orcid":false,"given":"Vernikka","family":"Woods","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0963-2870","authenticated-orcid":false,"given":"Seema","family":"Rawal","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7961-7453","authenticated-orcid":false,"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7028-9160","authenticated-orcid":false,"given":"Corry M.","family":"Jones","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-6735","authenticated-orcid":false,"given":"Rejeena","family":"Shrestha","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-2886","authenticated-orcid":false,"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0812-9346","authenticated-orcid":false,"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3947-4126","authenticated-orcid":false,"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"6Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9599-2246","authenticated-orcid":false,"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026030403074686300_bib1","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"2026030403074686300_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2026030403074686300_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026030403074686300_bib4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026030403074686300_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026030403074686300_bib6","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"2026030403074686300_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"2026030403074686300_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026030403074686300_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"2026030403074686300_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030403074686300_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"2026030403074686300_bib12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-14-1425","article-title":"pVHL\/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma","volume":"21","author":"Ruf","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026030403074686300_bib13","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"2026030403074686300_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Canc Res"},{"key":"2026030403074686300_bib15","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026030403074686300_bib16","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the harmony project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026030403074686300_bib17","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM","volume":"141","author":"Stong","year":"2023","journal-title":"Blood"},{"key":"2026030403074686300_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"key":"2026030403074686300_bib19","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov"},{"key":"2026030403074686300_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026030403074686300_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026030403074686300_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"2026030403074686300_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030403074686300_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","article-title":"CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance","volume":"41","author":"Nilsson","year":"2023","journal-title":"Cancer Cell"},{"key":"2026030403074686300_bib25","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res"},{"key":"2026030403074686300_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/14728222.12.3.341","article-title":"CD70 as a therapeutic target in human malignancies","volume":"12","author":"Grewal","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"2026030403074686300_bib27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"2026030403074686300_bib28","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEarchern","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026030403074686300_bib29","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","article-title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients","volume":"105","author":"Keats","year":"2005","journal-title":"Blood"},{"key":"2026030403074686300_bib30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br J Haematol"},{"key":"2026030403074686300_bib31","doi-asserted-by":"crossref","first-page":"109168","DOI":"10.1016\/j.clim.2022.109168","article-title":"NK cell therapy in relapsed refractory multiple myeloma","volume":"246","author":"Roshandel","year":"2023","journal-title":"Clin Immunol"},{"key":"2026030403074686300_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"2026030403074686300_bib33","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"key":"2026030403074686300_bib34","doi-asserted-by":"crossref","first-page":"101925","DOI":"10.1016\/j.xcrm.2024.101925","article-title":"Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets","volume":"6","author":"Moreno Rueda","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026030403074686300_bib35","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"2026030403074686300_bib36","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2026030403074686300_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026030403074686300_bib38","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026030403074686300_bib39","doi-asserted-by":"crossref","first-page":"626098","DOI":"10.3389\/fimmu.2021.626098","article-title":"GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"2026030403074686300_bib40","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/bloodadvances.2019000835","article-title":"A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation","volume":"3","author":"Li","year":"2019","journal-title":"Blood Adv"},{"key":"2026030403074686300_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0130\/3665761\/bcd-25-0130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0130\/3726029\/bcd-25-0130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/2\/234\/3740543\/bcd-25-0130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/2\/234\/3740543\/bcd-25-0130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:07:56Z","timestamp":1772611676000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/2\/234\/774793\/CD70-Targeting-CAR-NK-Cells-Overcome-BCMA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0130","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.31484197","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484176","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484173","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484182","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484161","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484191","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484188","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484200","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484155","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31484167","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8335723","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}